| Vol. 14.19 – 19 May, 2022 |
| |
|
|
PRMT Inhibition Induces a Viral Mimicry Response in Triple-Negative Breast Cancer | The authors identified MS023, an inhibitor of type I protein arginine methyltransferases (PRMTs), which has antitumor growth activity in TNBC. [Nature Chemical Biology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
N6-Methyladenosine Regulated FGFR4 Attenuates Ferroptotic Cell Death in Recalcitrant HER2-Positive Breast Cancer | Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, scientists identified FGFR4 as an essential gene following anti-HER2 treatment. [Nature Communications] |
|
|
|
Transcriptional Repression by FoxM1 Suppresses Tumor Differentiation and Promotes Metastasis of Breast Cancer | Using CRISPR-Cas9 engineering, investigators generated a mouse model that expressed Forkhead box M1 (FoxM1) harboring point mutations that blocked binding to Rb while retaining its ability to bind CREB-binding protein. [Cancer Research] |
|
|
|
DPYSL2 Interacts with JAK1 to Mediate Breast Cancer Cell Migration | Dihydropyrimidinase-like 2 (DPYSL2) knockout in mesenchymal-like breast cancer cells profoundly inhibited cell migration, invasion, stemness features, tumor growth rate, and metastasis. [Journal of Cell Biology] |
|
|
|
NSrp70 Suppresses Metastasis in Triple-Negative Breast Cancer by Modulating Numb/TβR1/EMT Axis | Multiple in vitro and in vivo functional analyses were used to study the effects of nuclear speckle-related protein 70 (NSrp70) on breast cancer metastasis. [Oncogene] |
|
|
|
RHAMM Expression Tunes the Response of Breast Cancer Cell Lines to Hyaluronan | Researchers used a unidirectional hyaluronan (HA) gradient to investigate in a high-throughput fashion the bi-directional communication between HA and breast cancer cell lines with different surface expression of CD44 and receptor for hyaluronan-mediated motility (RHAMM). [Acta Biomaterialia] |
|
|
|
RNA Binding Protein POP7 Regulates ILF3 mRNA Stability and Expression to Promote Breast Cancer Progression | The authors showed that expression of processing of precursor 7 (POP7) was frequently increased in breast cancer cells and in primary breast tumors. [Cancer Science] |
|
|
|
Antiproliferative and Apoptotic Potential of Methotrexate Lipid Nanoparticle in Murine Breast Cancer Model | Scientists evaluated the efficacy of novel methotrexate-loaded nanoparticles in vitro and in vivo in the treatment of breast cancer. [Nanomedicine] |
|
|
|
CircEIF3H-IGF2BP2-HuR Scaffold Complex Promotes TNBC Progression via Stabilizing HSPD1/RBM8A/G3BP1 mRNA | Investigators performed high-throughput RNA-seq in paired breast cancer tissues and adjacent normal tissues and discovered a novel circRNA, circEIF3H, which was upregulated in breast cancer tissues. [Cell Death Discovery] |
|
|
|
TRPC5OS Induces Tumorigenesis by Increasing ENO1-Mediated Glucose Uptake in Breast Cancer | Researchers elucidated the function of transient receptor potential channel 5 opposite strand (TRPC5OS) in aberrant metabolism mediated tumorigenesis. [Translational Oncology] |
|
|
|
Low Expression of PCK2 in Breast Tumors Contributes to Better Prognosis via Inducing Senescence of Cancer Cells | Verification in cultured breast cancer cells indicated that phosphoenolpyruvate carboxykinase 2 (PCK2) was significantly inhibited after therapy treatment. [IUBMB Life] |
|
|
|
|
Wnt Signaling in the Breast: From Development to Disease | Investigators dissect the fundamental role of Wnt signaling in mammary gland development and adult homeostasis and explore how defects are interlinked with cancer, with a focus on the breast. [Frontiers in Cell and Developmental Biology] |
|
|
|
The Potential Role of Nicotine in Breast Cancer Initiation, Development, Angiogenesis, Invasion, Metastasis, and Resistance to Therapy | The authors review the mechanistic function of nicotine in the initiation, development, angiogenesis, invasion, metastasis, and apoptosis of breast cancer with the main focus on nicotine acetylcholine receptors. [Breast Cancer] |
|
|
|
|
Zenith Epigenetics Announces Initiation of a Phase IIb Triple Negative Breast Cancer (TNBC) Clinical Trial | Zenith Epigenetics Ltd. announced the initiation of a Phase IIb TNBC clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna. [Zenith Epigenetics Ltd.] |
|
|
|
|
|
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| Jülich Research Centre – Jülich, Germany |
|
|
|
| Temple University – Philadelphia, Pennsylvania, United States |
| |
|
|
|